Evidence map›Paper›PMID 34959706›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

6'-

Michele Verboni, Simone Lucarini, Andrea Duranti

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Synthesis and Biological Evaluation of 6-Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michele VerboniDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, Italy.ORCID 0000-0001-5648-521X
Simone LucariniDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, Italy.ORCID 0000-0002-3667-1207
Andrea DurantiDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, Italy.ORCID 0000-0002-7531-4472

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycolipid surfactants are biocompatible and biodegradable compounds characterized by potential applications in various sectors including pharmaceuticals, cosmetics, agriculture, and food production. A specific overview regarding synthetic methodologies and properties of 6'-lactose-based surfactants is presented herein, particularly all the synthetic approaches to this class of lactose esters, such as enzymatic and traditional organic syntheses. Moreover, detailed descriptions of physicochemical data and biocompatibility properties of these molecules, that is, surface tension, critical micelle concentration, emulsifying ability, foaming, particle size distribution, biocompatibility, and safety, are described. Biological applications with a focus on permeability enhancing, antimicrobial activity, and antibiofilm properties of 6'-lactose-based esters are also reported.

Indexed as

enzymatic synthesisfatty acidsglycolipidslactose monoesterspermeability enhancerssugar-based surfactants

Identifiers

PMID34959706
PMCPMC8706069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.